Table 2.

Patient characteristics and immune checkpoint inhibitors response.

Case	Age/Sex	Histology	Stage	PD-L1	RET Fusion	Immunotherapy	Treatment Lines	Before or after RET-TKI	Response	PFS (months)
P1	63/F	Ade	IV	90%	KIF5B-RET	Pembrolizumab	1	Before	PR	5.6
P2	66/M	Ade	IV	NA*	JMJD1C-RET	Pemetrexed + Camrelizumab	3	–	SD	7.9
P3	55/M	Ade	IV	20%	KIF5B-RET	Pemetrexed + Carboplatin + Bevacizumab + Pembrolizumab	2	–	SD	7.2
P4	54/F	Ade	IV	NA*	KIF5B-RET	Pemetrexed + Carboplatin + Camrelizumab	1	–	PR	12.6
P5	48/M	Ade	IV	5%	KIF5B-RET	Pemetrexed + Carboplatin + Pembrolizumab	3	Before	SD	6.6
P6	43/M	Ade	IV	0	FXYD4-RET	Nab-paclitaxe + Bevacizumab + Tislelizumab	3	–	PR	6.6
P7	65/M	Ade	IV	80%	KIF5B-RET	Pemetrexed + Carboplatin + Pembrolizumab	1	–	SD	7.5
P8	63/M	Ade	IV	1%	KIF5B-RET	Pemetrexed + Carboplatin + Bevacizumab + Camrelizumab	2	Before	PD	1.5
P9	54/M	Ade	IV	NA*	KIF5B-RET	Pemetrexed + Carboplatin + Tislelizumab	1	–	PR	6.1
P10	47/F	LCNC	IV	0	KIF5B-RET	Nab-paclitaxe + Durvalumab	4	Before	SD	3.5
P11	56/F	Ade	IV	NA*	KIF5B-RET	Paclitaxe + Sintilimab	2	–	SD	4.7
P12	49/M	Ade	IV	35%	KIF5B-RET	Docetaxe + Nedaplatin + Pembrolizumab	2	–	PD	0.8
P13	79/M	Ade	IV	NA*	KIF5B-RET	Pembrolizumab + Anlotinib	2	–	PD	1.3
P14	63/M	Ade	IV	NA*	CCDC6-RET	Pemetrexed + Carboplatin + Bevacizumab + Toripalimab	1	–	SD	9.4
P15	65/F	Ade	IV	95%	KIF5B-RET	Pemetrexed + Carboplatin + Pembrolizumab	1	–	PR	5.6
P16	49/F	Ade	IV	90%	KIF5B-RET	Pemetrexed + Carboplatin + Camrelizumab	1	–	PR	5.1

Note: *NA defined as PD-L1 expression unknown.